Glenmark Pharmaceuticals Ltd - Company Profile
Powered by 
All the data and insights you need on Glenmark Pharmaceuticals Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Glenmark Pharmaceuticals Ltd Strategy Report
- Understand Glenmark Pharmaceuticals Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Glenmark Pharmaceuticals Ltd (Glenmark) focuses on the discovery and development of new chemical entities (NCEs). It develops and markets branded and generic formulations. The company's formulations business encompasses therapeutic areas such as dermatology, respiratory, and oncology. The company also has presence in other therapeutic areas such as diabetes, cardiovascular and oral contraceptives. The company manufactures and supplies active pharmaceutical ingredients (APIs). Glenmark has manufacturing facilities in India, Argentina, the US and Czech Republic. The company markets its products in North America, Japan, Latin America, Europe, India, Middle East North Africa (MENA), Asia and Russia, among others. Glenmark is headquartered in Mumbai, Maharashtra, India.
Headquarters
India
Address
B D S Marg, Chakala, Off Western Express Highway, Andheri (E), Mumbai, Maharashtra, 400099
Website
glenmarkpharma.com
Telephone
91 22 40189999
No of Employees
15,556
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GLENMARK (NSE)
Revenue (2022)
$1.5B
-5.9%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-68.4%
(2022 vs 2021)
Market Cap*
$3.6B
Net Profit Margin (2022)
XYZ
-66.4%
(2022 vs 2021)
* As of and is in US$
Glenmark Pharmaceuticals Ltd premium industry data and analytics
Products and Services
| Products | Services | Brands |
|---|---|---|
| Branded Formulations: | Contract Development and Manufacturing | Beat |
| Oncology | Ryaltris | |
| Respiratory | Tiogiva | |
| XYZ | XYZ | |
| XYZ | XYZ | |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Contracts/Agreements | In January, the company and Pfizer partnered to launch abrocitinib in India. |
| 2024 | Contracts/Agreements | In January, the company and Ichnos Sciences entered into a partnership to expedite new drug discovery in cancer treatment. |
| 2023 | Regulatory Approval | In October, the company secured ANDA approval for Apremilast Tablets. |
Competitor Comparison
| Key Parameters | Glenmark Pharmaceuticals Ltd | Teva Pharmaceutical Industries Ltd | Viatris Inc | Sun Pharmaceutical Industries Ltd | Aurobindo Pharma Ltd |
|---|---|---|---|---|---|
| Headquarters | India | Israel | United States of America | India | India |
| City | Mumbai | Tel Aviv | Canonsburg | Mumbai | Hyderabad |
| State/Province | Maharashtra | Tel Aviv | Pennsylvania | Maharashtra | Telangana |
| No. of Employees | 15,556 | 35,001 | 38,000 | 41,000 | 15,690 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Glenn Saldanha | Managing Director; Chairman | Executive Board | 2001 | - |
| Cherylann Pinto | Director; Director - Corporate Affairs | Executive Board | 2007 | - |
| V.S. Mani | Global Chief Financial Officer; Executive Director | Executive Board | 2017 | - |
| Dr. Nikhil Amin | President - Innovative Medicines Group; Chief Scientific Officer | Senior Management | 2022 | - |
| Alind Sharma | President; Chief Human Resources Officer - Global | Senior Management | 2022 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward